RenovoRx (RNXT) announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists. The principal manufacturer of RenovoCath devices is Medical Murray Inc., based in the U.S. in North Barrington, Illinois.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
- RenovoRx Delays Yearly Report Filing
- RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
- RenovoRx initiated with a Buy at H.C. Wainwright
- RenovoRx advnaces RenovoCath commercialization